Navigation Links
AIDS drug from sunflowers

Sunflowers can produce a substance which prevents the AIDS pathogen HIV from reproducing, at least in cell cultures. This is the result of research carried out by scientists at the University of Bonn in cooperation with the caesar research centre. For several years now the hopes for a completely new group of AIDS drugs have been pinned to what is known as 'DCQA'. However, the substance is only available in very small quantities and is thus extremely expensive. By using the Bonn method it could probably be produced for a fraction of the costs. The researchers have patented their method. Together with the Jülich Research Centre they now want to attempt to manufacture the substance on a large scale. They are looking for partners in industry to help them with this.

It all began with a small mould with the tongue-twisting name sclerotinia sclerotiorum. The pathogen responsible for the dreaded 'white stem rot' can, if the weather conditions are unfavourable, destroy an entire sunflower crop. However, some sunflowers survive the fungus attack more or less unscathed. They do this by producing specific antibodies which eventually put a stop to the fungus.

The agricultural engineer Claudio Cerboncini wanted to find out what chemical weapons the fungus-resistant sunflowers have at their disposal. In his PhD thesis for Professor Heide Schnabl of the Bonn Centre of Molecular Biotechnology (CEMBIO) Claudio infected different types with their sworn enemy. In this way he was able to isolate the antitoxins which the plants produce in response to the fungus. Among these was a substance which is also mentioned in the literature, albeit in a completely different context: this is dicaffeoyl quinic acid, or DCQA for short ?the highly prized prototype for a new group of AIDS drugs.

One million euros per gram

'Dicaffeoyl quinic acid can prevent the HI virus from reproducing, at least in cell cultures,' explains Claudio Cerboncini, who is now working at the caesar research centre. 'It is one of the few substances known today which inhibit viral integrase ?this is an enzyme which is essential if the pathogen is to reproduce.' In contrast to other enzymes medical experts expect there to be only a few side-effects from such integrase inhibitors. In the pharmaceuticals industry they are therefore seen as the great white hope for a completely new class of AIDS drugs. Initial clinical tests seem to confirm DCQA's potential.

'We need these substances to expand our arsenal of effective weapons against the disease,' Dr. Esther Vogt of the Immunological Out-Patient Service of Bonn University Clinic adds. 'It remains to be seen, however, whether they will prove to be as effective in clinical practice as they seem to be at present.'

DCQA occurs in the artichoke and wild chicory, though in extremely small doses. The market price is therefore currently ?,000 per milligram. 'We want to attempt to cultivate sunflower cells or other plant cells in a nutrient solution together with the mould sclerotinia sclerotiorum and then obtain the enzyme from the liquid,' CEMBIO researcher Ralf Theisen says. 'If things go according to plan, we could produce DCQA at a substantially reduced cost.'

From the ceiling of Ralf Theisen's office hangs the model of a Maxus rocket. As a botanist he is actually doing research on how plants react to gravity, and therefore recently sent some of his test objects into space in a rocket like that. 'We are investigating which genes plants switch on and off under particular gravity conditions,' he explains. 'However, with the methods we use we can also, for example, find out which genes the sunflowers activate when they produce DCQA in reaction to a fungus infection.'

This knowledge would make mass production of DCQA a distinct possibility. Even now chemists can 'copy' the substance, albeit only with great difficulty. 'The tricky bit is transferring the caffeoyl groups to the quinic acid,' Ralf Theisen says. 'The plants probably only have one enzyme, which acts as a catalyst for this transfer. If we can find the construction manual for this enzyme, i.e. the corresponding gene, and can smuggle it into the bacteria, the latter can produce the enzyme in large quantities. The critical step of synthesis would then be child's play and could be carried out on an industrial basis by using the fermentation technology available in Jülich.'


'"/>

Source:University of Bonn


Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... ... March 27, 2017 , ... A research team led ... grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. The ... treating coronary artery disease (CAD). Lam is an assistant professor at the Department ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... LEXINGTON, Mass. , March 24, 2017 ... pipeline of immune checkpoint antibodies and cancer vaccines, today ... The 7 th  Annual William Blair and Maidstone ... Event Space Alexandria Center in New York, ... March 29 at 9:40 am: ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseq™ Inherited Cancer DNA ... from industry experts to validate the ability ...
Breaking Biology Technology: